Original Research

Antimicrobial Activity of Iodoquinol 1%–Hydrocortisone Acetate 2% Gel Against Ciclopirox and Clotrimazole

Author and Disclosure Information

Commercially available topical formulations consisting of iodoquinol 1%–hydrocortisone acetate 2%, ciclopirox 0.77%, and clotrimazole 1%–betamethasone dipropionate 0.5% were assessed for their antimicrobial activity against cultures of Micrococcus luteus, Propionibacterium acnes, methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Corynebacterium aquaticum, Trichophyton mentagrophytes, Malassezia furfur, Microsporum canis, Candida albicans, Trichophyton rubrum, or Epidermophyton floccosum. At 1 and 5 minutes following inoculation into suspensions of each product, aliquots were removed, serially diluted, and plated onto appropriate agar to determine the log reduction in colony-forming units (CFUs) for each organism. Iodoquinol 1% produced the broadest and greatest antimicrobial activity as measured by a 3-log reduction of CFU, active against all microbes tested following incubation times of 1 or 5 minutes, except M luteus. By contrast, ciclopirox 0.77% and clotrimazole 1% showed activity against P aeruginosa and T rubrum, with ciclopirox also killing M luteus, P acnes, M canis, C albicans, and E floccosum at 5 minutes. Iodoquinol 1%–hydrocortisone acetate 2% also was the only product that showed effective antibacterial reduction of MRSA at 1 minute.


 

Recommended Reading

World Leaders Endorse HIV/AIDS-TB Screening
MDedge Dermatology
Mortality Gap Narrows Between HIV-Infected, General Population
MDedge Dermatology
Joint Commission Rules Tackle Infection Control : Hospitals will be required to have a surveillance program up and running by Jan. 1, 2010.
MDedge Dermatology
Stressed Health Care Systems are Driving MRSA Spread
MDedge Dermatology
MRSA Control Efforts Revved Up
MDedge Dermatology
Cleaning Products Drive Antimicrobial Resistance
MDedge Dermatology
Skin Infections in Young Athletes Demand Vigilance
MDedge Dermatology
Stewardship Program Explores Antimicrobial Use, Resistance
MDedge Dermatology
Guidelines Endorse Earlier Treatment of HIV
MDedge Dermatology
Psoriasis in the Patient With Human Immunodeficiency Virus, Part 2: Review of Treatment
MDedge Dermatology